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Abstract
Background: Porcine parvovirus (PPV) VP2 gene has been successfully expressed in many expression systems
resulting in self-assembly of virus-like particles (VLPs) with similar morphology to the native capsid. Here, a
pseudorabies virus (PRV) system was adopted to express the PPV VP2 gene.
Methods: A recombinant PRV SA215/VP2 was obtained by homologous recombination between the vector PRV
viral DNA and a transfer plasmid. Then recombinant virus was purified with plaque purification, and its identity
confirmed by PCR amplification, Western blot and indirect immunofluorescence (IFA) analyses. Electronic
microscopy of PRV SA215/VP2 confirmed self-assembly of both pseudorabies virus and VLPs from VP2 protein.
Results: Immunization of piglets with recombinant virus elicited PRV-specific and PPV-specific humoral immune
responses and provided complete protection against a lethal dose of PRV challenges. Gilts immunized with
recombinant viruses induced PPV-specific antibodies, and significantly reduced the mortality rate of (1 of 28)
following virulent PPV challenge compared with the control (7 of 31). Furthermore, PPV virus DNA was not
detected in the fetuses of recombinant virus immunized gilts.
Conclusions: In this study, a recombinant PRV SA215/VP2 virus expressing PPV VP2 protein was constructed using
PRV SA215 vector. The safety, immunogenicity, and protective efficacy of the recombinant virus were demonstrated
in piglets and primiparous gilts. This recombinant PRV SA215/VP2 represents a suitable candidate for the
development of a bivalent vaccine against both PRV and PPV infection.
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Background
Porcine parvovirus (PPV) is a major cause of the syn-
drome of reproductive failure observed in sows. The
infection occurs without clinical symptoms in adults.
However, the virus crosses the placental barrier, infect-
ing embryos and leading to stillbirths. Recent studies
have indicated that, in addition to inducing reproductive
failure, PPV also causes dermatitis, diarrhea, and
respiratory system disease [1-3]. A program of continu-
ous vaccination is required to avoid the substantial
economic losses associated with this globally prevalent
virus.
Parvovirus infections are controlled mainly by the
humoral immune responses [4], Therefore, it is hypothe-
sized that generation of effective immunity in sows prior
to conception will prevent PPV infection [5]. It is gener-
ally believed that active acquired immunity against PPV
provides lifelong protection against clinical diseases.
Classical vaccines based on inactivated viruses are still
in use [6]. However, safety considerations together with
poor PPV replication in vitro have intensified the need
to develop alternative vaccines.
The major structural protein, VP2 is the main target
for neutralizing antibodies in PPV. Many systems have
been used to express VP2 resulting in successful self-
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any medium, provided the original work is properly cited.assembly of virus-like particles (VLPs) with similar mor-
phology to the native capsid and identical hemagglutina-
tion activity compared with active PPV. The PPV VLPs
have been extensively studied due to their ability to
i n d u c eaw h o l er a n g eo fi m m u n er e s p o n s e s[ 7 ] .T h e
application of this technology is expected to be impor-
tant in the development of novel vaccines for PPV.
Live vaccines based on recombinant viruses have
played an important role in the development of new
vaccines. Live attenuated pseudorabies virus (PRV) has
been proven as an excellent vector for expression and
delivery of heterologous antigens in the development of
recombinant vaccines against infectious diseases in
swine [8-15] due to a number of advantageous charac-
teristics. The genome structure and genetic background
are relatively well defined and multiplication and stable
expression of foreign genes does not affect the stability
of the virus itself. Furthermore, the virus infects a wide
range of hosts which do not jeopardize human safety.
The large DNA genome of PRV is capable of accommo-
dating several kilobases (kb) of foreign DNA and a num-
ber of appropriate insertion sites and useful promoters
have been identified [16]. These insertion sites include
TK, PK, gE, gI, and gG genes, all of which are nonessen-
tial for viral replication [16,17]. Inactivation or deletion
of one or more of these genes leads to an attenuated
phenotype while retaining the replication ability of the
virus [18]. Based on the attenuated live vaccine, several
PRV recombinants expressing immunogens of heterolo-
gous pathogens, such as the glycoprotein E1 of classical
swine fever virus (CSFV) have been constructed and
vaccination with the recombinant PRV has been shown
to confer protection against Aujeszky’s disease and clas-
sical swine fever. These observations have clearly
demonstrated the significance of attenuated PRV in
development of bi- or multi-valent vaccines to control
animal diseases [15].
In this report, immunogenicity and protective efficacy
of a recombinant pseudorabies virus expressing PPV
VP2 protein was demonstrated in swine with the aim of
providing a novel vaccine to be used in prevention and
control of both PRV and PPV infections in the future.
Materials and methods
Virus, cells and plasmid
The parent virus PRV SA215, which has been widely
used in China to control Aujeszky’s disease, is a PRV Fa
derivative in which genes encoding three important
virulence factors (TK, gE, and gI) have been deleted.
Generation of the construct has been described in our
laboratory previously [19,20]. The PPV-SC1 strain was
isolated from the stillbirth of field pigs in Sichuan pro-
vince, China. Vero cells and ST cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, Gibco,
USA), supplemented with 10% (v/v) fetal calf serum
(FCS, Gibco, USA) , 100 IU/ml of streptomycin, and
100 IU/ml of penicillin at 37°C in a humidified 5% CO2
atmosphere. The transfer plasmid pPI-2.EGFP contain-
ing PRV homology region and enhanced green fluores-
cent protein (EGFP) gene was constructed in this
laboratory.
Construction of recombinant transfer plasmids
PPV viral DNA was extracted from the ST cells infected
by the PPV-SC1 strain and used as a template to
amplify the PPV VP2 gene using following pair of speci-
fic primers, Forward: 5’-tta ggt acc atg agt gaa aat gtg
g a ac- 3 ’,R e v e r s e :5 ’-ttt gga tcc gta taa ttt tct tgg tat
aag-3’. Restriction enzyme sites (Kpn Ia n dBamHI ,
indicated by underlining) were introduced into the for-
ward and reverse primers respectively for cloning pur-
poses.The 1740-bp PCR product was digested by Kpn I
and BamH I, and inserted into the corresponding sites
in the PRV transfer plasmid pPI-2.EGFP. The resulting
construct encoded EGFP at the N-terminus of VP2 gene
and was designated as pPI-2.EGFP.VP2. Identity of the
construct was confirmed by diagnostic restriction
enzyme digestion.
Generation of recombinant PRV SA215/VP2 virus
Vero cells were co-transfected with plasmid pPI-2.EGFP.
VP2 and genomic DNA of PRV SA215 using lipofecta-
mine TM 2000 reagent (Invitrogen, USA) according to
the instructions provided by the manufacturer. Infected
cells containing recombinant pseudorabies virus (PRV
SA215/VP2) were harvested when obvious cytopathic
effect (CPE) was observed (Figure 1). The recombinant
viruses were purified five times by plaque-formation
assay. In each round, green plaques identified by fluores-
cent microscopy were harvested, and the presence of
VP2 gene was confirmed by PCR amplifying.
Western blot and indirect immunofluorescence assay
VP2 protein expression in the recombinant PRV SA215/
VP2 was detected by Western blot analysis and IFA. For
Western blots, Vero cells were inoculated with PRV
SA215/VP2 or PRV SA215 for 72 h in 6 cm×10 cm cell
culture flasks. Twenty microliters of each of the virus-
infected cell lysates were separated by SDS-polyacryla-
mide gel electrophoresis (SDS-PAGE) followed by trans-
fer onto nitrocellulose membranes as previously
described [13]. Western blot was carried out using poly-
clonal anti-VP2 rabbit antibody (1:200 dilution) and
HRP-conjugated goat anti-rabbit IgG (1:5000 dilution,
Southern Biotechnology, USA) as the primary and sec-
ondary antibodies respectively.
For IFA, Vero cells were seeded onto a slide in a six-
well plate and then inoculated with PRV SA215/VP2 or
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were harvested for indirect immunofluorescence assay as
previously described [13]. Polyclonal anti-VP2 rabbit
antibody (1:200 dilution) and FITC conjugated anti-rab-
bit IgG (1:100 dilution, Pierce, USA) were used as the
primary and secondary antibodies respectively. Fluores-
cent foci were detected by fluorescence microscopy.
Electron microscopy analysis
PRV SA215/VP2 and PRV SA215 were grown separately
in Vero cells in 6 cm × 10 cm cell culture flasks until
obvious CPE were visible. Following digestion with tryp-
sin, Vero cells were harvested and ultrathin section sam-
ples were prepared for analysis using electron
microscopy. Samples were examined using a Hitachi H-
600A transmission electron microscope (Hitachi, Japan).
Animal immunization and challenge
Twenty eight-day-old piglets (n = 20) were obtained
locally. These animals had not received PRV and PPV
vaccination and tested negative for PRV and PPV antibo-
dies. The piglets were divided into four groups (n = 5 per
group). Group 1 was injected intramuscularly (i.m.) with
5×10
5 TCID50 of recombinant PRV SA215/VP2. Group 2
was injected i.m. with one standard dose of vector virus
PRV SA215. Group 3 was injected i.m. with 2 ml inacti-
vated PPV vaccine (China Animal Husbandry Industry
Company Ltd., China). Booster injection was given with
the same dose at 14 days post-vaccination. Group 4 was
inoculated with 2 ml PBS and served as negative control.
Animals were bled at 0, 14, 28, 42 and 56 d after immuni-
zation and sera were collected for immunoassays. Ani-
mals were challenged with 1×10
6 TCID50 PRV Fa strain
at day 56 d post-vaccination. Clinical symptoms and sur-
vival were recorded until 14d post-challenge.
Six 6-months-old primiparous gilts (negative for PRV
and PPV antibodies) were divided into two groups (n =
3 per group). Group 1 was injected i.m. at 0 d with
5×10
5 TCID50 PRV SA215/VP2. Group 2 was not
immunized and served as negative control. All gilts were
challenged at 77 d with 1×10
6.5 TCID50 PPV SC1 strain
via the ear vein. Sera were collected at 0, 28, 77, 114 d.
Mummified, stillborn and live foetuses were counted
after delivery. Tissue samples from lung, liver, spleen
and kidney were obtained from all foetuses, pooled and
analyzed for the presence of PPV by PCR.
Serum neutralization test for PRV
Sera were inactivated at 56°C for 30 min and then
diluted two-fold in DMEM in a 96-well flat-bottomed
tissue culture plates (Nunc, USA). Virus suspension
with a titer of 100 TCID50 in 50 μl was added to each
serum sample and then incubated for 1 h at 37°C and
5% CO2. Vero cell suspension (50 μl) was added to each
well and incubated for 3 to 5 days. Appropriate serum,
virus and cell controls were included in this test. The
plates were monitored for CPE by light microscopy.
Antibodies detection of PPV
Anti-PPV antibody titers were detected by indirect
ELISA using a commercial kit (The GreenSpring TM
Porcine Parvovirus ELISA Test Kit, Shenzhen Lvshiyuan
Biotechnology Co., Ltd, China) according to the instruc-
tions provided by the manufacturer.
Statistical analysis
An analysis of variance (ANOVA) and a Student’s t-test
were used to evaluate differences in humoral immune
responses between groups. P-values of < 0.05 were con-
sidered statistically significant.
Figure 1 Construction of recombinant PRV SA215/VP2. The PRV SA215 genomic DNA was approximately 150 kb including a unique long
region (UL), a unique short region (US), internal repeat (IR) and terminal repeat (TR). The thymidine kinase gene (TK) was partially deleted. PRV
SA215/VP2 was generated from PRV SA215/VP2. The LacZ expression cassette was replaced with the EGFP/VP2 expression cassette by
homologous recombination.
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Construction and identification of recombinant
pseudorabies virus PRV SA215/VP2
Recombinant PRV SA215/VP2 was generated through
homologous recombination of transfer plasmid pPI-2.
EGFP.VP2 and genomic DNA of vector virus PRV
SA215 (Figure 1). Obvious CPE were observed approxi-
mately three days after co-transfection when PRV
SA215/VP2 was harvested. Recombinant viruses were
purified for five times by plaque-formation assay. Infec-
tion Vero cells showed green fluorescence by fluorescent
microscopy (Figure 2). The recombinant virus was iden-
tified by PCR amplification of the VP2 gene (Figure 3).
The growth rate and viral yields of recombinant viruses
were similar to those of the vector PRV SA215. These
results confirmed that insertion of the foreign gene did
not affect the normal replication of PRV.
Expression of VP2 gene in recombinant PRV SA215/VP2
To analyze expression of the VP2 protein, Vero cells
were infected with the recombinant PRV SA215/VP2 or
vector PRV SA215. Cell proteins were analyzed by Wes-
tern blot and indirect immunofluorescence. A specific
93-kDa band correlating with the EGFP-VP2 fusion pro-
tein was detected in PRV SA215/VP2 infected cells by
Western blot analysis, but not in the vector PRV SA215
infected control (Figure 4A). Moreover, in the IFA
assay, fluorescence staining was observed in Vero cells
infected PRV SA215/VP2 (Figure 4B), but not in the
PRV SA215 infected control (Figure 4C).
Electron microscopy analysis
Electronic microscopy analysis confirmed the presence
of two kinds of virus particles in the same Vero cells
infected with PRV SA215/VP2. Virus particles of
approximately 150 nm exhibited envelope protein and
morphological features similar to those of pseudorabies
virus. Smaller virus particles of approximately 30-40 nm
were identified as empty capsids and exhibited a similar
morphology to porcine parvovirus (Figure 5). These
results indicate VP2 VLP assembly in the Vero cells
infected with recombinant PRV SA215/VP2.
Neutralizing antibodies against PRV induced by PRV
SA215/VP2 and challenge
Neutralizing antibodies against PRV were detected 14
days post-immunization in the sera of piglets immu-
nized with PRV SA215/VP2 or the PRV SA215 vector.
No significant differences were detected in the levels of
neutralizing antibodies in piglets immunized with PRV
SA215/VP2 compared with those vaccinated with PRV
SA215 (P > 0.05) (Table 1). No neutralizing antibodies
against PRV were be detected in piglets injected with
inactivated PPV vaccine and PBS (Table 1).
Fifty-six days after immunization, all piglets were
challenged with 1×10
6 TCID50 of the virulent PRV Fa
strain. Before challenge, all piglets were clinically
healthy. After challenge, piglets immunized with PRV
SA215/VP2 or PRV SA215 showed no clinical signs of
Aujeszky’s disease. However, in the inactivated PPV vac-
cine group and the PBS control group, some piglets
showed neurological symptoms of PRV infection before
death (Table 2). These data indicate that the recombi-
nant PRV SA215/VP2 provided complete protection
against a lethal PRV challenge.
Induction of PPV specific antibodies by PRV SA215/VP2
PPV specific antibodies in sera of piglets were determined
using an indirect ELISA assay. Two weeks after vaccina-
tion, antibodies against PPV were detected in the sera of
piglets immunized with PRV SA215/VP2 and inactivated
PPV. The levels of antibodies increased from 14 d to 56 d
Figure 2 Expression of the fused EGFP-VP2 protein in Vero cell foci detected by fluorescence microscopy (magnification 400 ×).( A )
Fluorescence microscope image of PRV SA215/VP2 infected Vero cells 36 h post-infection; (B) Light microscope image of PRV SA215/VP2
infected Vero cells 36 h post-infection; (C) Merged images of (A) and (B).
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PRV SA215/VP2 group was significantly higher than that
in the inactivated PPV vaccine group at 14 d and 28 d
post-immunization (P < 0.01) and significantly lower at 56
d (P < 0.05). There were no significant differences between
these two groups at 42 d after immunization. In contrast,
no PPV specific antibodies were detected in the PRV
SA215 immunized group and PBS control group (Figure
6). These results demonstrate that a PPV-specific antibody
response was induced in animals immunized with the
recombinant virus.
Induction of PPV specific antibodies in gilts by PRV
SA215/VP2 and viral challenge
All primiparous gilts remained clinically healthy
throughout the experiment. A positive PPV specific
antibody response was detected at 28 d in gilts immu-
nized with recombinant PRV SA215/VP2. The level of
specific antibodies was maintained up to 77 d. PPV
specific antibodies were not detected in the non-
immunized group. The specific antibody titer increased
in all animals following viral challenge at 77 d (Figure
7). Mortality rates of foetuses of the immunized and
non-immunized gilts were 3.6% (1/28) and 22.6% (7/
31), respectively. PPV virus DNA was detected in all
control group foetuses by PCR, but in none of the
recombinant PRV SA215/VP2 immunized group
(Table 3). These results indicate that the foetuses of
gilts vaccinated with PRV SA215/VP2 were not
infected following PPV challenge.
Discussion
Vaccines play a critical role in the control of viral dis-
eases. Vaccines against both PRV and PPV are exten-
sively used all over the world. However, the use of such
vaccines in clinical practice is limited by considerations
Figure 3 Identification of recombinant PRV SA215/VP2 by PCR
amplication of VP2 gene. PCR products were analyzed by 0.8%
gel agarose electrophoresis. Lanes: (M) Marker DL2000; (1-3) Samples
of Vero cells infected with PRV SA215/VP2; (4) Positive control, PPV;
(5) Vero cells infected with vector virus PRV SA215.
Figure 4 Analysis of VP2 gene expression.( A )W e s t e r nb l o t
analysis of VP2 protein expressed by infected Vero cells. Lanes: (M)
Pre-stained protein markers, (1) Vector PRV SA215; (2) Recombinant
PRV SA215/VP2. The 93-kDa band represents EGFP and VP2 fusion
protein. (B and C) Indirect immunofluorescence analysis of VP2
protein expressed in Vero cells infected with recombinant PRV
SA215/VP2 (B) and vector PRV SA215 (C). Cells infected with
recombinant PRV SA215/VP2 developed immunofluorescence (B),
and cells infected with vector virus PRV SA215, did not develop
immunofluorescence (C).
Figure 5 Electron microscope analysis of Vero cells infected
PRV SA215/VP2. Two types of virus particles were observed in the
same Vero cell. Recombinant PRV particles are indicated by the
black arrow. Empty virus-like particles probably formed from PPV
VP2 protein are indicated by the white arrow.
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Therefore, research is now focused on developing a
bivalent vaccine.
The parent PRV strain SA215 used in this trial is an
approved vaccine strain which is strongly immunogenic
and has been widely used to prevent and control pseu-
dorabies diseases in China. This PRV vaccine strain has
been attenuated by deletion of the genes encoding three
important virulence factors (TK, gE, and gI) of the Fa
strain. It has been approved as a new veterinary medi-
cine and is the first animal virus-based genetically engi-
neered vaccine in China.
Many systems have been successfully used for the
expression of the PPV VP2 gene resulting in self-assem-
bly of VLPs. Such systems include adenovirus, yeast,
and particularly, the insect cell-baculovirus system
[7,21,22] which has been used for mass production.
Their expression products assembled into VLPs were
similar in size and morphology to the original virions.
The highly immunogenic VLPs have been shown to pro-
tect breeding sows against reproductive failure following
virulent virus challenge [23], which is in accordance
with the data obtained in this study. However, the
potential for contamination of PPV VLPs with the vec-
tors used in these approaches has raised serious safety
concerns about the use of these recombinant vaccines
[24,25]. In this study, the pseudorabies virus system,
which was extensively applied to express other heterolo-
gous antigens, was used to express the PPV VP2 gene
successfully, without any of the described safety issues.
Recently, PPV VLPs have been shown to express for-
eign polypeptides in certain positions, resulting in the
successful production of many highly immunogenic pep-
tides, and the induction of strong antibody, helper-T-
cell, and cytotoxic T-lymphocyte responses [26]. Sedlik
et al. prepared the hybrid virus-like particles by self-
assembly of the modified porcine parvovirus VP2 capsid
protein, carrying a CD8+ T cell epitope from the lym-
phocytic choriomeningitis virus nucleoprotein. Immuni-
zation of mice with these hybrid pseudoparticles,
without any additional adjuvant, induced strong cyto-
toxic T lymphocyte (CTL) responses against both pep-
tide-coated and virus-infected target cells [27]. Pan et al.
used PPV VLPs as a new generation of non-replicative
vectors for delivery of a PCV2 epitope, which was
expressed in adenovirus. The expressed product signifi-
cantly enhanced both antibody-specific and cell-
mediated immune response to PPV and PCV2 [28]. It
can be speculated that the PRV SA215/VP2 constructed
in this study could be used for the insertion of foreign
polypeptides in specific positions of the VP2 gene to
enhance immunogenicity of PRV and PPV, and further-
more, may be developed as a multivalent vaccine.
The VP2 and EGFP fusion protein facilitated screening
and purification of the recombinant virus from infected
Vero cells although the issue of correct folding of the
VP2 protein was subsequently addressed. An indepen-
dent VP2 expression cassette was constructed which
induced a higher level of antibody production. Positive
identification of VP2 protein by Western blot analysis
and IFA assay using a polyclonal anti-VP2 rabbit anti-
body indicated correct folding of VP2 protein, thus, pro-
viding the essential component for vaccine development.
Safety of the recombinant virus was indicated by the
absence of clinical signs related to Aujeszky’s disease in
piglets and gilts immunized with recombinant virus.
Furthermore, no difference in virulence was detected
between the recombinant virus and the vector virus.
Efficacy experiments demonstrated that piglets immu-
nized with the recombinant virus elicited PRV-specific
and PPV-specific humoral immune responses and pro-
vided complete protection against a lethal PRV
Table 1 PRV-specific neutralizing antibodies (NA) in piglets (X ± SD, n = 5)
Group 0d
a 14d 28d 42d 56d
PRV SA215/VP2 -
b 18.69 ± 3.19 57.61 ± 11.98 65.73 ± 8.04 67.8 ± 6.95
PRV SA215 - 20.12 ± 2.51 62.05 ± 12.52 66.22 ± 11.03 67 ± 6.63
Inactivated PPV vaccine - - - - -
PBS - - - - -
Note:
aDays after vaccination.
b NA titers < 2
Table 2 Piglets immunized with recombinant PRV SA215/VP2 survival following challenge with a lethal dose of
virulent PRV Fa strain
Group Vaccination dose Challenge dose Number of piglets Number of death Protection (%)
PRV SA215/VP2 5×10
5 TCID50 1×10
6 TCID50 5 0 100
PRV SA215 5×10
5 TCID50 1×10
6 TCID50 5 0 100
Inactivated PPV vaccine 2ml 1×10
6 TCID50 54 2 0
PBS 2 ml 1×10
6 TCID50 52 4 0
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[8,10,29]. Furthermore, gilts immunized with the recom-
binant virus induced PPV-specific antibodies and pro-
vided complete protection against challenge with the
PPV-SC1 strain. These results demonstrated the immu-
nogenicity of the recombinant virus.
Moreover, this genetically engineered vaccine also
allowed differentiation between vaccinated and the natu-
rally infected pigs, thus contributing to the Aujeszky’s
disease eradication program.
Conclusions
A recombinant virus PRV SA215/VP2 expressing the
PPV VP2 protein was constructed using the PRV SA215
as a vector. This study demonstrated the safety, immu-
nogenicity, and protective efficacy of this vaccine in pig-
lets and primiparous gilts. This recombinant virus
represents a suitable candidate for further clinical eva-
luation of its application as a bivalent vaccine against
both PRV and PPV infection.
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